Pacific Edge's revenue climbs, US future still uncertain

A boom in Pacific Edge’s Cxbladder test sales boosted the firm’s operating revenue soar by 71%, with a helping hand from favourable exchange rates.Chief executive Peter Meintjes said the 2023 financial year had been a year of “enormous change and achievement” for the cancer diagnostic company.“Pacific Edge is geared for growth,” he told the NZX.Operating revenue for the twelve months to March 31 rose $19.6 million, up from $11.4m in the previous year while total revenue jumped 88% to $26.1m.The revenue climb...